Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results
from this proposal will validate the use of a novel antibody developed at
Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of
the disease. The investigators work will also provide direct evidence that LPL is expressed
on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow
and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: email@example.com
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.